TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25237116

Group type: EXPERIMENTAL
Intervention: CBD 300 mg/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CBD 75 mg/day
Number of subjects: 21
Study: 22261900

Group type: EXPERIMENTAL
Intervention: brief monthly CPR practice with voice‐activated manikins
Number of subjects: 606

Group type: COMPARATOR
Intervention: no practice
Number of subjects: 606
Study: 20924214

Group type: EXPERIMENTAL
Intervention: Lifetime alcohol intake of more than 292 kg
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cumulative alcohol intake
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Proportion of heavy drinkers
Number of subjects: 146

Group type: COMPARATOR
Intervention: Alcohol intake
Number of subjects: 146
Study: 17986302

Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 84

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 84
Study: 15979768

Group type: EXPERIMENTAL
Intervention: Single morning dose (400 ml) of carbohydrate-rich drink (CL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intake of the drink in the evening and in the morning before the clamp (LL)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Overnight fasting (CC)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Single evening dose (800 ml) of carbohydrate-rich drink (LC)
Number of subjects: 6
Study: 11937141

Group type: EXPERIMENTAL
Intervention: Cook Echo-Tip catheter
Number of subjects: 251

Group type: COMPARATOR
Intervention: Wallace catheter
Number of subjects: 251
Study: 10518228

Group type: EXPERIMENTAL
Intervention: Monophasic oral contraceptives with different progestogen types (desogestrel, gestodene, levonorgestrel, norgestimate) and ethinyl estradiol doses (50, 30, and 20 micrograms)
Number of subjects: 730
Study: 8198904

Group type: EXPERIMENTAL
Intervention: Oral clonidine 300 micrograms, 1 h before and 12 h after surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral clonidine and placebo
Number of subjects: 40
Study: 2452308

Group type: EXPERIMENTAL
Intervention: TTS-10
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: TTS-20
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: TTS-40
Number of subjects: 67

Group type: COMPARATOR
Intervention: Normal left ventricular function (control group)
Number of subjects: 67
Study: 29655700

Group type: EXPERIMENTAL
Intervention: Nutraceutical combination containing fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols
Number of subjects: 80
Study: 27251519

Group type: EXPERIMENTAL
Intervention: One-stage posterior sagittal anorectoplasty (PSARP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Three-stage operation (colostomy, PSARP, and closure of colostomy)
Number of subjects: 40
Study: 24297318

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT‐based intervention)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Deferred‐entry control group (CG)
Number of subjects: 15
Study: 21511980

Group type: EXPERIMENTAL
Intervention: Coping Skills Training
Number of subjects: 39
Study: 20507376

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SRP
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Er:YAG laser + SRP
Number of subjects: 27

Group type: COMPARATOR
Intervention: Supragingival scaling
Number of subjects: 27
Study: 18657134

Group type: EXPERIMENTAL
Intervention: 400 mg of lactose
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 16188753

Group type: EXPERIMENTAL
Intervention: High volume packed red blood cell (PRBC) transfusions (20 ml/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard volume packed red blood cell (PRBC) transfusions (15 ml/kg)
Number of subjects: 20
Study: 12153814

Group type: EXPERIMENTAL
Intervention: Endosurgical DCR
Number of subjects: 69

Group type: COMPARATOR
Intervention: Endolaser (Holmium:YAG) DCR
Number of subjects: 69

Group type: COMPARATOR
Intervention: Lacrimal irrigation
Number of subjects: 69

Group type: COMPARATOR
Intervention: Functional endoscopic dye test (FEDT)
Number of subjects: 69
Study: 10341394

Group type: EXPERIMENTAL
Intervention: Filtration leukocytapheresis (LCP) therapy, performed 3 times with 1 week intervals between procedures.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham procedures (Control group)
Number of subjects: 0
Study: 8862491

Group type: EXPERIMENTAL
Intervention: Nafarelin (400 micrograms/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Buserelin (900 micrograms/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Buserelin
Number of subjects: 22
Study: 1994844

Group type: EXPERIMENTAL
Intervention: Maternal iodine supplementation during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 6188922

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0
Study: 31477439

Group type: COMPARATOR
Intervention: Tübingen palatal plate (TPP)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Prone positioning
Number of subjects: 443
Study: 27943220

Group type: EXPERIMENTAL
Intervention: Lorazepam (0.1 mg/kg, to a maximum of 4 mg)
Number of subjects: 145
Study: 26931195

Group type: EXPERIMENTAL
Intervention: Hospitalisation in an SSU (intervention)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Standard care (Department of Internal Medicine) (control)
Number of subjects: 430
Study: 25151200

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 202

Group type: COMPARATOR
Intervention: Aripiprazole vs Ziprasidone
Number of subjects: 202

Group type: COMPARATOR
Intervention: Aripiprazole vs Quetiapine
Number of subjects: 202

Group type: COMPARATOR
Intervention: Quetiapine vs Ziprasidone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 202
Study: 22071008

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 19874051

Group type: EXPERIMENTAL
Intervention: Antibody self‐oriented immunoprobe on magnetic nanoparticles (MNPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BA‐mediated covalent antibody immobilization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple immunoassay using the new immunonanoprobe
Number of subjects: 0
Study: 17497543

Group type: EXPERIMENTAL
Intervention: Health Realization treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-Step treatment
Number of subjects: 0
Study: 15018625

Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A (Botox®) injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 0
Study: 12390854

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEI)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Calcium channel blocker or alpha-receptor blocker (Control)
Number of subjects: 36
Study: 9661601

Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg sublingually)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (25 mg i.v. bolus)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sodium nitroprusside or nicotine
Number of subjects: 2
Study: 7631600

Group type: EXPERIMENTAL
Intervention: Coagulation monitoring including single daily estimation of PTF1 + 2 (target range < 0.5 nmol/L) and FII activity (15% to 35%); adjustment of heparin and phenprocoumon dosages based on PTF1 + 2 and FII measurements.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard coagulation tests (TT, aPTT, INR, AT III, fibrinogen) for anticoagulation monitoring.
Number of subjects: 120
Study: 2076373

Group type: EXPERIMENTAL
Intervention: UVAB rays (350 +/‐ 32 nm)
Number of subjects: 10

Group type: COMPARATOR
Intervention: UVB rays (300 +/‐ 5 nm)
Number of subjects: 10
Study: 7448680

Group type: EXPERIMENTAL
Intervention: Probucol (1 g per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clofibate
Number of subjects: 16
Study: 30915633

Group type: EXPERIMENTAL
Intervention: HCAG chemotherapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: FLAG chemotherapy
Number of subjects: 98
Study: 28239295

Group type: EXPERIMENTAL
Intervention: Person-centred care intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional care (control)
Number of subjects: 96
Study: 27858735

Group type: EXPERIMENTAL
Intervention: Valproic Acid (VPA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 24629480

Group type: EXPERIMENTAL
Intervention: Brief behavioral cessation treatment (1 in-person session and 3 phone calls)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intensive behavioral cessation treatment (3 in-person sessions and 5 phone calls)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both treatment groups (brief and intensive)
Number of subjects: 50
Study: 22606232

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 18710702

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (1.5 mg)
Number of subjects: 0
Study: 17684654

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ketoprofen
Number of subjects: 24
Study: 14504956

Group type: EXPERIMENTAL
Intervention: Top-down implementation of health regulations regarding rest times
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Longer rest times during high season
Number of subjects: 440
Study: 11784873

Group type: EXPERIMENTAL
Intervention: Normal-calcium, low-animal-protein, low-salt diet (30 mmol calcium, 52 g animal protein, 50 mmol sodium chloride)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-calcium diet (10 mmol calcium)
Number of subjects: 120
Study: 9744372

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% applied once daily for 6 months
Number of subjects: 223

Group type: COMPARATOR
Intervention: Switching from timolol to latanoprost
Number of subjects: 223

Group type: COMPARATOR
Intervention: Timolol treatment
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Latanoprost treatment
Number of subjects: 223
Study: 8553147

Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg once daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2916889

Group type: EXPERIMENTAL
Intervention: Once-daily normal saline irrigation
Number of subjects: 32

Group type: COMPARATOR
Intervention: No irrigation (control)
Number of subjects: 32
Study: 1097596

Group type: EXPERIMENTAL
Intervention: benztropine
Number of subjects: 18

Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 18

Group type: COMPARATOR
Intervention: chlorpromazine
Number of subjects: 18
Study: 29939302

Group type: EXPERIMENTAL
Intervention: Prebiotic (fructooligosaccharide, FOS, 12 g/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 12 g/day)
Number of subjects: 50
Study: 28812167

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic (5-ALA) followed by 595-nm pulsed dye laser therapy (5-ALA PDL)
Number of subjects: 181

Group type: COMPARATOR
Intervention: 595-nm pulsed dye laser therapy alone (PDL alone)
Number of subjects: 181
Study: 25842221

Group type: COMPARATOR
Intervention: Injectable procaine benzylpenicillin-gentamicin for 7 days (group A)
Number of subjects: 3564

Group type: EXPERIMENTAL
Intervention: Injectable gentamicin and oral amoxicillin for 7 days (group B)
Number of subjects: 3564

Group type: EXPERIMENTAL
Intervention: Injectable procaine benzylpenicillin-gentamicin for 2 days, then oral amoxicillin for 5 days (group C)
Number of subjects: 3564

Group type: EXPERIMENTAL
Intervention: Injectable gentamicin for 2 days and oral amoxicillin for 7 days (group D)
Number of subjects: 3564

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C, D)
Number of subjects: 3564
Study: 23433966

Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 537

Group type: COMPARATOR
Intervention: Established lifestyle recommendations
Number of subjects: 537

Group type: COMPARATOR
Intervention: Established lifestyle recommendations plus Dietary Approaches to Stop Hypertension dietary pattern
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Change in dietary self-efficacy (DSE)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Change in exercise self-efficacy (ESE)
Number of subjects: 537
Study: 22035508

Group type: EXPERIMENTAL
Intervention: High-dose pirfenidone (1800 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose pirfenidone (1200 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19645171

Group type: EXPERIMENTAL
Intervention: Femoral-Sciatic Nerve Block (FSB)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 56
Study: 17919161

Group type: EXPERIMENTAL
Intervention: Theory-based interactive postpartum sexual health education programme (experimental group, n = 84)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Routine postpartum teaching (control group, n = 82)
Number of subjects: 166
Study: 15126738

Group type: EXPERIMENTAL
Intervention: Semont maneuver
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 156

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Semont maneuver, Flunarizine, No treatment
Number of subjects: 156
Study: 11324149

Group type: EXPERIMENTAL
Intervention: ESWT focussed on the calcified region
Number of subjects: 50

Group type: COMPARATOR
Intervention: ESWT focussed on the insertion of the supraspinatus tendon
Number of subjects: 50
Study: 9207580

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 8281528

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10‐20 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisinopril (10‐20 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 3732378

Group type: EXPERIMENTAL
Intervention: Cibenzoline administered 1 h prior to food
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cibenzoline administered with a standard breakfast
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cibenzoline administered 1 h after a standard breakfast
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cibenzoline under fasting conditions
Number of subjects: 18
Study: 31567375

Group type: EXPERIMENTAL
Intervention: T-180 mg-24 h
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: T-90 mg-24 h
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: T-90 mg-12 h
Number of subjects: 102

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 102
Study: 29943831

Group type: EXPERIMENTAL
Intervention: DRL_BZ
Number of subjects: 149

Group type: COMPARATOR
Intervention: RMP
Number of subjects: 149

Group type: COMPARATOR
Intervention: RP
Number of subjects: 149
Study: 27126300

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 51

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 51
Study: 25092564

Group type: EXPERIMENTAL
Intervention: CPT plus thalidomide (5 mg/kg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CPT plus thalidomide (8 mg/kg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CPT plus thalidomide (10 mg/kg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CPT plus thalidomide (all doses)
Number of subjects: 43
Study: 22610355

Group type: EXPERIMENTAL
Intervention: Nedaplatin (NDP) at AUC 12
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nedaplatin (NDP) calculated by AUC with Ishibashi's formula
Number of subjects: 15

Group type: COMPARATOR
Intervention: CPT‐11 at a fixed dose of 60 mg/m2
Number of subjects: 15
Study: 20455850

Group type: EXPERIMENTAL
Intervention: Iscador (mistletoe therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine alone or any other best of care (not including Iscador)
Number of subjects: 0
Study: 18627327

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cisplatin-based combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study: 16116008

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% plus epinephrine 1:200,000
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 43
Study: 12195348

Group type: EXPERIMENTAL
Intervention: zidovudine plus lamivudine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: zidovudine plus abacavir
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: lamivudine plus abacavir
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: nelfinavir (symptomatic children)
Number of subjects: 113

Group type: COMPARATOR
Intervention: placebo (asymptomatic children)
Number of subjects: 113
Study: 10189982

Group type: EXPERIMENTAL
Intervention: Therapeutic community and community residences treatment environments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 0
Study: 7584934

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (delapril)
Number of subjects: 1936

Group type: COMPARATOR
Intervention: Ca antagonist
Number of subjects: 1936

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1936
Study: 1691882

Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg i.v.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Morphatropin (1 ml s.c.)
Number of subjects: 21
Study: 396336

Group type: EXPERIMENTAL
Intervention: Inactivated Port Chalmers (H3ChN2Ch) influenza vaccine (group A)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Neuraminidase-specific (Heq1N2Ch) influenza vaccine (group B)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 3
Study: 31089894

Group type: EXPERIMENTAL
Intervention: Bone-anchored annular closure device (ACD)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Lumbar discectomy only (Control)
Number of subjects: 554
Study: 28013097

Group type: EXPERIMENTAL
Intervention: Prequit Nicotine Patch
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Prequit Nicotine Gum
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: In-Person Counseling
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Combination of Prequit Gum and In-Person Counseling
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Withdrawal reduction and reduced prequit smoking
Number of subjects: 637
Study: 25700931

Group type: EXPERIMENTAL
Intervention: FGF23 levels
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: FePi levels
Number of subjects: 166
Study: 24129243

Group type: EXPERIMENTAL
Intervention: 40‐h dyadic and triadic communication skills training programme
Number of subjects: 95
Study: 21217614

Group type: EXPERIMENTAL
Intervention: Oral ketorolac 10 mg plus submucous local tramadol (50 mg diluted in 1 mL saline solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral ketorolac 10 mg plus submucous local placebo (1 mL saline solution)
Number of subjects: 30
Study: 19270300

Group type: EXPERIMENTAL
Intervention: RDTs performed by study staff
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: RDTs performed by health facility staff
Number of subjects: 1827

Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 1827
Study: 16894413

Group type: EXPERIMENTAL
Intervention: (99m)Tc(V)DMSA
Number of subjects: 31

Group type: COMPARATOR
Intervention: (67)Ga‐C
Number of subjects: 31
Study: 15271709

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11730183

Group type: EXPERIMENTAL
Intervention: HFA flunisolide 170 microg, twice daily
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: HFA flunisolide 340 microg, twice daily
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: CFC flunisolide (250, 500, or 1,000 microg, twice daily)
Number of subjects: 669

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 669
Study: 9473975

Group type: EXPERIMENTAL
Intervention: Binaural listening array with arm separations of 30 degrees, 45 degrees, and 60 degrees, signal-to-noise ratios of +5, -5, and -15 dB.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binaural listening array
Number of subjects: 0
Study: 7935522

Group type: EXPERIMENTAL
Intervention: EMG during fatigue protocol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: VMG during fatigue protocol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Raw EMG signals
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: VMG records
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-frequency content of VMG signal
Number of subjects: 11
Study: 3280532

Group type: EXPERIMENTAL
Intervention: 2 cycles of MOPP and radiotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 66
Study: 29405670

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125% 5 mL on radial and median nerves at the elbow (dNB group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no distal nerve blocks)
Number of subjects: 52
Study: 27930564

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (DEX) 1 μg/kg over 10 minutes, followed by 0.5 μg/kg/h continuous infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (0.9% saline)
Number of subjects: 60
Study: 24604142

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vestibular exercises
Number of subjects: 40
Study: 23124178

Group type: EXPERIMENTAL
Intervention: Solution-Focused Therapy (SFT)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Short-Term Psychodynamic Psychotherapy (SPP)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Long-Term Psychodynamic Psychotherapy (LPP)
Number of subjects: 326
Study: 20969686

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine infusion
Number of subjects: 55
Study: 19046248

Group type: EXPERIMENTAL
Intervention: Cranberry treatment for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 30